BTRX 246040Alternative Names: BTRX-246040; LY 2940094
Latest Information Update: 12 Nov 2016
At a glance
- Originator Eli Lilly
- Developer BlackThorn Therapeutics; Eli Lilly
- Class Antidepressants; Small molecules
- Mechanism of Action Nociceptin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Neurological disorders
- Discontinued Alcoholism; Major depressive disorder